🔍

AMANTA - Amanta Healthcar

📊 NSE: AMANTA 🏢 Pharmaceuticals 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Amanta Healthcare Promoter Bhavesh Patel Acquires 48,151 Shares via Open Market

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 27 Feb 2026, 05:00 PM

Shri Bhavesh Patel, a promoter of Amanta Healthcare Limited, has increased his stake by purchasing 48,151 equity shares from the open market. The acquisition took place over two trading sessions on February 26 and February 27, 2026. This transaction was disclosed under the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such insider buying typically signals strong promoter confidence in the company's future prospects and intrinsic value.

Promoter Shri Bhavesh Patel purchased a total of 48,151 equity shares.
The acquisition was conducted through open market transactions on February 26 and 27, 2026.
The disclosure was filed in compliance with Regulation 7(2) of SEBI Insider Trading rules.
The move indicates increased 'skin in the game' by the promoter group.

💡 Investors should view this promoter buying as a positive sign of internal confidence, though it should be weighed against the company's overall financial performance.

CRISIL Upgrades Amanta Healthcare’s Long-Term Rating to 'BBB/Stable' on Improved Financial Profile

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 16 Feb 2026, 04:32 PM

CRISIL has upgraded Amanta Healthcare's long-term rating to 'BBB/Stable' and short-term rating to 'A3+', reflecting a significantly strengthened financial position. The upgrade follows a successful IPO that raised Rs 126 crore, boosting net worth to Rs 211 crore as of September 2025 and reducing gearing from 2.02 to 0.84. The company maintains healthy operating margins of 21-22% and is expanding capacity for its Steriport and SVP brands, expected to go live in April 2026. This improved credit profile suggests lower borrowing costs and better financial stability for future growth.

Long-term credit rating upgraded to 'CRISIL BBB/Stable' from 'CRISIL BBB-/Stable' for Rs 245 crore bank facilities.
Net worth increased to Rs 211 crore from Rs 96 crore following a Rs 126 crore IPO infusion.
Debt-to-equity (gearing) ratio improved significantly to 0.84x from 2.02x as of September 2025.
Operating margins remain healthy at approximately 22% for the first half of fiscal 2026.
Capacity expansion for Steriport and SVP brands is scheduled for completion by April 2026 to drive future revenue.

💡 Investors should view this upgrade as a sign of reduced financial risk and improved balance sheet strength following the IPO. Monitor the timely commencement of the new capacity in April 2026 as it is the primary catalyst for medium-term growth.

Amanta Healthcare Q3 PAT Rises 8.1%; Targets ₹150 Cr Incremental Revenue from Expansion

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 16 Feb 2026, 02:37 PM

Amanta Healthcare reported a steady Q3 FY26 with revenue growing 9.8% YoY to ₹75 crores and PAT increasing 8.1% to ₹5 crores. The company is nearing a major growth phase, doubling its SteriPort capacity to 12 crore bottles per annum with commercialization expected in April 2026. Management anticipates an incremental revenue potential of ₹150 crores from the combined LVP and SVP expansions. Additionally, a 10.8 MW captive solar plant is expected to save ₹9 crores annually starting Q1 FY27, which will significantly enhance operating leverage.

Q3 FY26 revenue grew 9.8% YoY to ₹75 crores, while 9M PAT surged 51% YoY to ₹9 crores.
SteriPort capacity doubling to 12 crore bottles/year with commercialization slated for April 2026.
Total incremental revenue potential of ₹150 crores from SteriPort and SVP expansions.
10.8 MW captive solar plant to be commissioned by Q1 FY27, targeting ₹9 crores in annual cost savings.
EBITDA margins remained healthy at 21.3% for the 9-month period despite one-time IPO expenses.

💡 Investors should monitor the successful ramp-up of the new SteriPort capacity in April 2026 as it is the primary driver for the projected ₹150 crore revenue growth. The stock remains attractive for long-term investors given the improving return ratios and structural cost advantages from the upcoming solar project.

Amanta Healthcare Publishes Q3 FY26 Financial Results in Newspapers

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 02:13 PM

Amanta Healthcare Limited has formally published its financial results for the quarter ended December 31, 2025, in compliance with SEBI regulations. The results were previously approved by the Board of Directors in their meeting held on February 10, 2026. The advertisements appeared in the February 12, 2026, editions of Business Standard (English) and Jai Hind (Gujarati). This is a standard regulatory procedure and does not contain new financial data beyond what was already disclosed to the exchanges.

Financial results for the quarter ended December 31, 2025, were published on February 12, 2026.
The Board of Directors approved the quarterly results on February 10, 2026.
Publications were made in Business Standard (English) and Jai Hind (Gujarati) newspapers.
Filing is in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 No action is required as this is a routine regulatory filing. Investors should refer to the actual financial statements released on February 10 to evaluate the company's quarterly performance.

Amanta Healthcare Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 05:47 PM

Amanta Healthcare Limited has officially released the audio recording of its Earnings Conference Call for the third quarter of FY26. The recording, which follows the company's initial intimation on February 6, 2026, is now available on the company's investor relations website. This disclosure is part of the mandatory compliance under Regulation 30 of SEBI (LODR) Regulations, 2015. Investors can access the recording to hear management's detailed discussion on the financial results and operational performance for the period ending December 31, 2025.

Audio recording for Q3 FY26 Earnings Conference Call is now publicly available.
The filing is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Recording can be accessed via the company's official website at https://www.amanta.co.in/investors.
This follows the prior notification regarding the investor meet issued on February 6, 2026.

💡 Investors should listen to the recording to understand management's perspective on Q3 performance and future guidance. No immediate action is required as this is a routine regulatory disclosure.

Amanta Healthcare Q3 PAT Up 8% YoY; 9MFY26 PAT Surges 51% to ₹9.3 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 01:54 PM

Amanta Healthcare reported a steady performance for Q3FY26 with revenue growing 9.84% YoY to ₹74.49 crore. The nine-month (9MFY26) performance was particularly strong in terms of profitability, with PAT surging 51.28% YoY to ₹9.3 crore. EBITDA margins for the 9-month period improved by 42 bps to 21.31%, although quarterly margins saw a slight compression of 159 bps. The company is currently executing a capacity expansion for high-margin SteriPort and SVP products, which is expected to drive growth from Q4 onwards.

9MFY26 PAT increased by 51.28% YoY to ₹9.3 crore, driven by operational efficiency.
Q3FY26 Revenue grew 9.84% YoY to ₹74.49 crore, reflecting volume-led demand.
9MFY26 EBITDA margins expanded by 42 bps to 21.31% despite quarterly fluctuations.
The company is scaling high-margin SteriPort and SVP capacities to accelerate growth.
Green energy initiatives are being implemented for structural cost optimization.

💡 Investors should monitor the commissioning of the new capacities in Q4, as management expects accelerated growth. The significant jump in 9-month profitability suggests improving operational leverage.

Amanta Healthcare Approves Q3 FY26 Unaudited Financial Results

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 01:46 PM

Amanta Healthcare Limited's Board of Directors approved the standalone unaudited financial results for the quarter and nine months ended December 31, 2025. The statutory auditors, Price Waterhouse Chartered Accountants LLP, provided a Limited Review Report with an unmodified opinion, suggesting no material discrepancies in the reporting. The meeting was held on February 10, 2026, ensuring timely regulatory compliance with SEBI listing obligations. Investors should note that the audit opinion confirms the financial statements are prepared in accordance with Indian Accounting Standards.

Board approved standalone unaudited financial results for the quarter and nine months ended December 31, 2025
Statutory auditor Price Waterhouse Chartered Accountants LLP issued a Limited Review Report with an unmodified opinion
The board meeting was conducted on February 10, 2026, between 12:00 PM and 01:00 PM
Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

💡 Investors should review the detailed profit and loss statements to assess the company's margin performance and revenue growth. The clean auditor's report provides a level of assurance regarding the integrity of the financial disclosures.

Amanta Healthcare Appoints Urmil Oza as Senior Management; Shailesh Shah Steps Down

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 10 Feb 2026, 01:14 PM

Amanta Healthcare Limited has announced changes to its Senior Management Personnel (SMP) effective February 10, 2026. Shri Urmil Oza, the current Vice President of Engineering, has been elevated to the SMP category, bringing 30 years of total experience, including 26 years with the company. Concurrently, Shri Shailesh Shah has been removed from the SMP list. These changes reflect internal organizational restructuring and leadership continuity within the engineering and production departments.

Shri Urmil Oza included as Senior Management Personnel effective February 10, 2026
Urmil Oza has 30 years of total work experience, with 26 years at Amanta Healthcare
Shri Shailesh Shah removed from the Senior Management Personnel list
Oza's expertise covers production engineering, utility equipment, and government compliance

💡 This is a routine management update and does not require immediate action. Investors should view the promotion of a 26-year company veteran as a positive sign for operational stability.

Amanta Healthcare Schedules Q3 & 9M FY26 Earnings Call for February 11, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 06 Feb 2026, 09:30 PM

Amanta Healthcare Limited has scheduled its earnings conference call for Wednesday, February 11, 2026, at 3:00 PM IST. The management team, including the Managing Director and CFO, will discuss the company's financial performance for the third quarter and the nine-month period ending December 31, 2025. This call provides a platform for analysts and institutional investors to receive business updates and seek clarifications on the latest financial results. Pre-registration is required for participants to join the session hosted by Go India Advisors.

Earnings call scheduled for February 11, 2026, at 03:00 PM IST.
Focus on financial performance for Q3 and 9M ended December 31, 2025.
Key participants include MD & Chairman Bhavesh Patel and CFO Paras Mehta.
Universal dial-in numbers provided are +91 22 6280 1557 and +91 22 7115 8383.

💡 Investors should monitor the call for management commentary on revenue growth and margin sustainability. It is an essential event for assessing the company's operational progress and future guidance.

Amanta Healthcare Opens Special Window for Physical Share Dematerialisation (Feb 2026-2027)

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 02 Feb 2026, 11:42 AM

Amanta Healthcare has announced a special one-year window for the transfer and dematerialisation of physical securities, running from February 5, 2026, to February 4, 2027. This initiative follows a SEBI circular aimed at resolving legacy issues for shares purchased or sold prior to April 1, 2019, which were previously rejected due to documentation deficiencies. Investors can now re-lodge their transfer deeds with the Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited. This move facilitates the conversion of old physical holdings into electronic format, ensuring regulatory compliance.

Special window for dematerialisation open from February 5, 2026, to February 4, 2027
Applies to securities sold or purchased prior to the April 1, 2019, regulatory cutoff
Targets previously rejected or un-attended transfer requests due to document deficiencies
Registrar and Transfer Agent (RTA) for the process is MUFG Intime India Private Limited
Complies with SEBI Circular dated January 30, 2026, regarding ease of investment

💡 Legacy shareholders holding physical certificates should utilize this one-year window to dematerialise their holdings. For most market participants, this is a routine regulatory update with no impact on the company's financial performance.

Amanta Healthcare Appoints GoIndia Advisors LLP as Investor Relations Agency

🟢 POSITIVE ⭐ 3/10

ROUTINE 📅 10 Jan 2026, 11:48 AM

Amanta Healthcare Limited has officially engaged GoIndia Advisors LLP, Mumbai, as its Investor Relations (IR) Agency. Announced on January 10, 2026, this move is aimed at enhancing the company's communication and transparency with the investor community. The agency will provide advisory services to help manage stakeholder relations and market visibility. This step is typical for companies looking to professionalize their outreach and improve analyst coverage.

Amanta Healthcare has appointed M/s. GoIndia Advisors LLP as its Investor Relations Agency.
The agency will provide Investor Relations Advisory Services to the company effective January 10, 2026.
The appointment is made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.
Contact details for the IR agency have been provided to facilitate shareholder and analyst communication.

💡 This is a routine administrative update that signals a commitment to better investor communication. Investors should monitor if this leads to more frequent updates, better quality investor presentations, or increased analyst coverage.

Amanta Healthcare Submits SEBI Compliance Certificate for Quarter Ended Dec 31, 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 02:18 PM

Amanta Healthcare Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms that share certificates received for dematerialization during the quarter ended December 31, 2025, were processed within prescribed timelines. The registrar verified that the certificates were mutilated and cancelled, and the depositories' names were updated in the register of members. This is a standard administrative filing ensuring regulatory compliance regarding shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Share Transfer Agent, MUFG Intime India Private Limited
Confirms that security certificates for dematerialization were mutilated and cancelled after verification
Verification ensures depository names are substituted in the register of members within timelines

💡 No action is required from investors as this is a routine regulatory filing. Investors should continue to monitor the company's operational performance and upcoming financial results.

Amanta Healthcare Corrects Solar Plant Capacity to 10.8 MWp for Captive Consumption

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 02 Jan 2026, 05:05 PM

Amanta Healthcare Limited has clarified a significant clerical error regarding its solar power project, correcting the capacity from 10.8 KWp to 10.8 MWp. The company has re-executed its agreement with Zodiac Energy Limited to reflect this 1,000x increase in planned capacity. The 10.8 MWp plant will be located in Kheda, Gujarat, and is dedicated to captive consumption. This move is expected to substantially reduce the company's long-term energy costs and improve its ESG profile.

Corrected solar power plant capacity from 10.8 KWp to 10.8 MWp
Agreement re-executed with Zodiac Energy Limited on January 02, 2026
Project located at Village Baroda, District Kheda, Gujarat
Plant intended for captive consumption to reduce operational electricity expenses
No other terms or conditions of the original agreement have been changed

💡 Investors should view this correction positively as a 10.8 MWp plant represents a significant infrastructure investment compared to the previously stated minor installation. Monitor for future updates regarding the commissioning date and the resulting impact on operating margins.

Amanta Healthcare to Install 10.8 KWp Solar Power Plant for Captive Consumption

🟢 POSITIVE ⭐ 3/10

EXPANSION 📅 30 Dec 2025, 03:36 PM

Amanta Healthcare Limited has entered into an agreement with Zodiac Energy Limited for the installation of a solar power plant. The 10.8 KWp facility will be located at Village Baroda in the Kheda district of Gujarat. This project is designed for captive consumption, aimed at reducing the company's reliance on external power sources and lowering operational costs. The company has stated that detailed information will be disclosed upon the successful commissioning of the plant.

Agreement signed with Zodiac Energy Limited on December 30, 2025
Installation of a 10.8 KWp Solar Power Plant for captive electricity generation
Project site located at Village Baroda, Ta- Matar, District Kheda, Gujarat
Strategic move to optimize utility costs and improve ESG compliance

💡 This is a minor operational update indicating a focus on cost-efficiency and sustainability. Investors should view this as a routine positive development with limited immediate impact on the stock price.

Amanta Healthcare to Close Trading Window from January 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 01:11 PM

Amanta Healthcare Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is ahead of the declaration of the unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons and their relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be notified at a later date.

Trading window closure effective from January 1, 2026.
Closure pertains to the financial results for the quarter and nine months ending December 31, 2025.
Restriction applies to insiders, connected persons, and designated employees.
Window to reopen 48 hours after the official announcement of financial results.
Board meeting date for result approval is yet to be determined.

💡 No action is required as this is a routine regulatory filing. Investors should monitor for the upcoming announcement of the board meeting date to track the company's quarterly performance.

View All AMANTA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 8.5% YoY to INR 281 Cr in FY24 from INR 259 Cr in FY23. Growth is primarily driven by the fluid therapy segment (LVP and SVP) and the high-margin Steriport segment. For H1 FY25, the company reported sales of INR 140 Cr, with a projected annual growth of 8-10% for the full fiscal year 2025.

Geographic Revenue Split

The company maintains a presence in both domestic and international markets, including Cambodia and Zimbabwe. While specific percentage splits are not disclosed, exports are identified as a primary driver for the projected 8-10% revenue growth in FY25 and are expected to increase further following the Steriport capacity expansion.

Profitability Margins

Operating margins have remained steady between 20-22% over the last five fiscals. The margin was 20.7% in FY24 and improved to approximately 22% during the first five months of FY25. PAT margin improved from -0.8% (INR -2 Cr loss) in FY23 to 1.3% (INR 4 Cr profit) in FY24.

EBITDA Margin

Operating EBITDA margin stood at 20.7% in FY24. The company maintains a core profitability range of 20-22%, which is supported by a shift toward high-value specialty products like Steriport and cost optimization measures, despite volatility in raw material costs.

Capital Expenditure

Planned capital expenditure of INR 90 Cr is scheduled for fiscals 2025 and 2026 to expand Steriport capacity. This is funded through INR 40 Cr in debt, INR 20 Cr via private placement of equity, and the remaining INR 30 Cr through internal accruals and promoter loans.

Credit Rating & Borrowing

CRISIL reaffirmed a 'CRISIL BBB-/Stable' long-term rating and 'CRISIL A3' short-term rating. Interest coverage ratio was 1.74 times in FY24. Borrowing costs are expected to decline following debt refinancing at lower rates in FY25.

⚙️ Operational Drivers

Raw Materials

The primary raw materials are imported plastic granules, which are used for bottle manufacturing and packaging. These materials are crude oil derivatives, making the company's cost structure highly sensitive to global oil price fluctuations.

Import Sources

Plastic granules are imported to ensure quality standards for parenteral products, though specific countries of origin are not listed beyond the requirement for high-grade medical plastics.

Key Suppliers

Not specifically named in the documents, but procurement is linked to global petrochemical markets for plastic granules.

Capacity Expansion

As of March 31, 2024, installed capacity includes 675 lakh bottles of Large Volume Parenteral (LVP), 2,400 lakh bottles of Small Volume Parenteral (SVP), and 849 lakh bottles of Steriport. The INR 90 Cr capex aims to significantly increase Steriport capacity by FY26.

Raw Material Costs

Raw material costs are a significant portion of the 55-60% revenue share attributed to the high-volume parenteral division. AHL manages these costs through a focus on higher-value products to offset the lack of bargaining power in low-value segments.

Manufacturing Efficiency

Manufacturing facilities in Kheda, Gujarat are ISO-certified and cGMP compliant. Efficiency is reflected in the sustained 20-22% operating margins despite raw material price pressure.

Logistics & Distribution

AHL utilizes an extensive distribution network of nearly 289 distributors to reach domestic and international markets.

📈 Strategic Growth

Expected Growth Rate

8-10%

Growth Strategy

Growth will be achieved through an INR 90 Cr capacity expansion in the Steriport segment, increasing the contribution of high-value-added products, and expanding export footprints. The company also filed a DRHP on September 26, 2024, to fund further capacity enhancements.

Products & Services

Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) for fluid therapy, formulations, antibiotics, anti-fungals, ophthalmic solutions, diuretics, and other injectables.

Brand Portfolio

Steriport (specialty parenteral brand).

New Products/Services

Expansion of the Steriport product line is expected to be the primary driver of the 8-10% revenue growth forecast for FY25.

Market Expansion

Targeting increased penetration in international markets such as Cambodia and Zimbabwe, supported by the Steriport capacity ramp-up through FY26.

Market Share & Ranking

AHL is described as one of the leading players in the parenteral business in India, though specific market share percentage is not provided.

Strategic Alliances

Engaged GoIndia Advisors LLP in January 2026 as an Investor Relations agency to manage capital market communications.

🌍 External Factors

Industry Trends

The parenteral industry is shifting toward high-value specialty injectables. AHL is positioning itself by expanding its Steriport capacity to move away from the low-margin, highly competitive standard LVP/SVP markets.

Competitive Landscape

Faces intense competition from both domestic and international parenteral manufacturers, particularly in the low-value fluid therapy segments.

Competitive Moat

Moat is built on the 'Steriport' brand, a large network of 289 distributors, and 30+ years of promoter experience. Sustainability depends on the successful transition to a higher-margin product mix to buffer against commodity price swings.

Macro Economic Sensitivity

Highly sensitive to global crude oil prices due to plastic granule requirements and domestic inflation which may affect operating costs.

Consumer Behavior

Increased demand for specialized fluid therapy and injectables in healthcare settings is driving the shift toward products like Steriport.

Geopolitical Risks

Trade barriers or regulatory changes in export markets like Cambodia and Zimbabwe could impact the projected growth from the export segment.

⚖️ Regulatory & Governance

Industry Regulations

Pricing is regulated by the National Pharmaceutical Pricing Authority (NPPA), which restricts the company's ability to pass on raw material price hikes to customers.

Environmental Compliance

Manufacturing facilities are ISO-certified and cGMP (current Good Manufacturing Practice) compliant, which are mandatory for pharmaceutical production.

⚠️ Risk Analysis

Key Uncertainties

Volatility in crude oil prices could impact operating margins by more than 200 basis points if costs cannot be passed on. The success of the INR 90 Cr capex is critical for maintaining the 8-10% growth trajectory.